1 published article · Updated continuously
34 trials tracked for Anaplastic large cell lymphoma: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 737 citations.
Showing the 34 most-cited and recently-updated of 34 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Several agents have been evaluated and established in clinical trials for anaplastic large cell lymphoma. Brentuximab vedotin was assessed in a Phase 3 trial 1. Panobinostat has been evaluated across multiple Phase 2 studies [10, 11].
Chemotherapeutic and immunotherapeutic agents also show established evidence. Bendamustine hydrochloride was evaluated in two separate Phase 2 trials [6, 16]. Fludarabine phosphate was assessed in a Phase 2 trial 12, while cyclophosphamide was evaluated across three Phase 2 studies [18, 19, 22]. Alemtuzumab was also established through multiple Phase 2 investigations [14, 21].
Safety data for these established interventions include specific observations on graft-versus-host disease (GVHD). In trials involving fludarabine phosphate, the incidence of Grade III/IV GVHD was reported as 2% and 4% respectively 17, while alemtuzumab showed a Grade III-IV acute GVHD incidence of 25% 14.
AI synthesis of 8 cited trials, updated Aug 2, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
